<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943800</url>
  </required_header>
  <id_info>
    <org_study_id>14736B</org_study_id>
    <nct_id>NCT00943800</nct_id>
  </id_info>
  <brief_title>Combined Haploidentical-Cord Blood Transplantation for Adults and Children</brief_title>
  <official_title>Combined Haploidentical-Cord Blood Transplantation for Adults and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the rate of engraftment with combined haploidentical-cord
      blood transplantation. The secondary objective is to evaluate the incidence and severity of
      acute and chronic graft-versus-host disease (GVHD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2006</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the rate of engraftment with combined haploidentical-cord blood</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the rates of GVHD with combined haploidentical-cord blood (acute &amp; chronic)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Good Risks patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients transplanted in remission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk Patients eligible for radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk Patients not eligible for radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine-Melphalan &amp; Rabbit antithymocyte globulin (r-ATG)</intervention_name>
    <description>Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.</description>
    <arm_group_label>Good Risks patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Infusion of haploidentical donor, umbilical cord blood</description>
    <arm_group_label>Good Risks patients</arm_group_label>
    <arm_group_label>High Risk Patients eligible for radiation</arm_group_label>
    <arm_group_label>High Risk Patients not eligible for radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cells Collections</intervention_name>
    <description>Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.</description>
    <arm_group_label>Good Risks patients</arm_group_label>
    <arm_group_label>High Risk Patients eligible for radiation</arm_group_label>
    <arm_group_label>High Risk Patients not eligible for radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)</intervention_name>
    <description>Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.</description>
    <arm_group_label>High Risk Patients eligible for radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Busulfan, and ATG</intervention_name>
    <description>Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.</description>
    <arm_group_label>High Risk Patients not eligible for radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be eligible for this study if they have any one of the diseases that are
        known to be cured after allogeneic stem cell transplantation.

          1. Relapsed or refractory acute leukemia (myeloid or lymphoid)

          2. Acute leukemia in first remission at high-risk for recurrence

          3. Chronic myelogenous leukemia in accelerated phase or blast-crisis

          4. Chronic myelogenous leukemia in chronic phase

          5. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma

          6. Chronic lymphocytic leukemia, relapsed or with poor prognostic features

          7. Multiple myeloma

          8. Myelodysplastic syndrome

          9. Chronic myeloproliferative disease

         10. Hemoglobinopathies

         11. Aplastic anemia

        Exclusion Criteria:

          1. Zubrod performance status &gt; 2

          2. Life expectancy is severely limited by concomitant illness

          3. Patients with severely decreased LVEF or impaired pulmonary function tests(PFT's)

          4. Estimated Creatinine Clearance &lt;50 ml/min

          5. Serum bilirubin&gt; 2.0 mg/dl or SGPT &gt;3 x upper limit of normal

          6. Evidence of chronic active hepatitis or cirrhosis

          7. HIV-positive

          8. Patient is pregnant

          9. Patient or guardian not able to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Artz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 8;118(24):6438-45. doi: 10.1182/blood-2011-08-372508. Epub 2011 Oct 5.</citation>
    <PMID>21976674</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Appropriate candidate for transplantation</keyword>
  <keyword>An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

